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Introduction
            The Wolff-Parkinson-White (WPW) syndrome has been a known clinical entity for over
fifty years. In 1967 Durrer et al postulated WPW syndrome was due to an accessory pathway,
bypassing the AV node, from the atria to the ventricles1. This was later confirmed by epicardial
mapping. WPW is the second most common cause of paroxysmal supraventricular tachycardias
in the western world and the most common cause in China2. WPW syndrome has a prevalence of
1.5 to 3.1 per 1000 persons in western countries3,4,5 . Patients with the WPW syndrome may
present with palpitations, presyncope, syncope, or sudden cardiac death (SCD). In some patients
the first and only manifestation of the disease is SCD. This is more likely to occur in the setting
of atrial fibrillation with a rapid ventricular response. Electrocardiographic findings of WPW
syndrome consist of preexcitation manifested by a shortened PR interval (<120 msec), a widened
QRS (>100 msec) a delta wave (abnormal initial QRS vector) and supraventricular tachycardia.
The EKG finding of preexcitation is a result of early ventricular depolarization through the
accessory pathway. SVT can occur with retrograde or antigrade conduction through the accessory
pathway  forming  the   basis   of   the   so-called   “macro-reentrant”  arrhythmia  model6.   Rapid
conduction through the accessory pathway in the setting of atrial fibrillation markedly increases
the risk of SCD7. We recently identified the gene responsible for familial Wolff-Parkinson-
White8. The gene (PRKAG2) which encodes for a protein AMPK (AMP- activated protein
kinase) was identified as the causal gene. Missense (single nucleotide change) mutations in this
gene were identified in families with WPW. Six such mutations have been identified. Along with
preexcitation  the affected families had conduction abnormalities (AV block) and cardiac
hypertrophy. 
Genetics of WPW
            Familial WPW syndrome has an autosomal dominant mode of inheritance. In autosomal
dominant inheritance 50% of the offspring inherit the mutated gene and are at risk of developing
the disease and affects males and females equally. In autosomal dominant mode of inheritance
only one copy of the gene has to be mutated to cause the disease as opposed to autosomal
recessive where both copies must have the mutations. We first performed genetic linkage
analysis to locate the chromosomal location (locus) followed by the candidate gene approach to
identify the gene in a family with an inherited form of WPW. The locus was on chromosome 7
(7q3) and the gene identified to be PKRAG2 which encodes for the gamma-2 subunit (non-
catalytic subunit) of AMPK. Since this initial discovery five more mutations in the same gene
have been identified. All of the mutations have been missense mutations in the PKRAG2 gene.
Missense mutations are mutations in which a single nucleotide is substituted by another
nucleotide inducing a change of a single amino acid in the final protein product. AMPK is a
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protein that is made up of three subunits an alpha subunit, beta subunit (38 kDa) and a gamma
subunit (36 kDa). PKRAG2 is the gene that encodes for the gamma-2 subunit of AMPK and it
contains 16 exons (the region of the gene that is translated into amino acids) and is made up of
569 amino acids.
Table 1           Mutations in PRKAG2 responsible for Human WPW syndrome
Protein   Mutation    Locus        Type
AMPK(gamma2)  Arg302Glu     7q3     missense
AMPK(gamma2) Thr400Asn      7q3     missense
AMPK(gamma2) Asn488Ile     7q3     missense
AMPK(gamma2) Arg531Gly     7q3     missense
AMPK(gamma2) His142Arg      7q3     missense
AMPK(gamma2) Leu insertion         7q3     missense
Functions of AMPK
            AMPK is a heterotrimeric protein which consists of alpha, beta, and gamma subunits. The
gamma subunit has been characterized as the non-catalytic subunit. There are at least three
isoforms of the gamma subunit (PKRAG1, PKRAG2, and PKRAG3). PKRAG1 and PKRAG2
are highly expressed in skeletal and cardiac muscle, whereas PKRAG3 expression is restricted to
skeletal muscle9.  Familial WPW syndrome is caused by mutations in the gamma-2 isoform
(PRKAG2) of AMPK. AMP-activated protein kinase (AMPK) serves as an energy sensor for the
cell10. In times of energy depletion and/or stress it is activated. Stressors that have been known to
activate AMPK include hypoxia, ischemia, exercise, and starvation10. This enzyme is activated
by high AMP/ATP ratios and deactivated by low AMP/ATP ratios10. In energy depleted states
(low ATP, high AMP) it is phosphorylated by AMPKK and is transformed to its active form.
This process is reversed when ATP levels are restored. ATP interferes with the AMP/AMPK
interaction and diminishes the ability of AMPKK to phosphorylate AMPK. Therefore it is the
ratio of AMP/ATP that determines the level of AMPK activation. AMPK has a multitude of
physiological roles. Primarily it increases fatty acid oxidation and glucose uptake during times of
stress10 and it also decreases glycogen synthesis. AMPK inhibits acetyl-coA carboxylase it leads
to a decrease in the synthesis of malonyl CoA. Since malonyl CoA is an inhibitor of fatty acid
oxidation this leads to increased fatty acid oxidation. AMPK increases GLUT-4 a protein
responsible for transport of glucose from the extracellular space to the intracellular space, thereby
making glucose available for ATP production. In vitro studies have demonstrated that activation
of AMPK inhibits glycogen synthase thus decreasing the amount of intercellular glycogen. These
actions of AMPK classify it as a catabolic enzyme that responds to stress to maintain energy
homeostasis.
Clinical Characteristics of WPW syndrome
            WPW can present clinically with palpitations, pre-syncope, syncope or SCD (sudden
cardiac death). Familial WPW syndrome was described in a large French-Canadian family in
198611. In this family the members that were affected showed clinical findings that consisted of
preexcitation, conduction abnormalities, and cardiac hypertrophy. We were fortunate to obtain
access to the family and identify the responsible gene. Preexcitation is defined as early
depolarization of the ventricles. This early depolarization is manifested on a 12-lead EKG, as a
short PR interval (<120 msec), and prolonged QRS (>100 msec), with the appearance of a delta
wave (slurring of the QRS). Adult cardiac conduction begins at the SA-node and proceeds
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through the atria, AV-node, HIS-bundle, left/right bundles, throughout the ventricles. Patients
with familial WPW syndrome have an accessory pathway that bypasses the normal cardiac
conduction. The accessory pathway is usually an accessory conduction bundle connecting the
atria and the ventricles. Hence the normal delay that occurs at the AV-node can be avoided by
conduction through the accessory pathway. The presence of an accessory pathway also provides a
reentrant   circuit   and   the   risk   of   developing   SVT   (supraventricular   tachycardias).   The
development of SVT in the presence of preexcitation constitutes the WPW syndrome12.
            Familial WPW syndrome differs from other forms of WPW syndrome in that affected
individuals also develop cardiac conduction abnormalities usually around the fourth decade of
life8. Conduction abnormalities involve AV-nodal, ventricular as well as the accessory pathway.
Treatment of patients often requires placement of a permanent pacemaker. It is thought this
slowing is secondary to diffuse progressive myopathic process13. Family members afflicted with
familial WPW syndrome also develop thickening of the myocardium. Cardiac hypertrophy has
been demonstrated in these patients by ultrasound. The development of cardiac hypertrophy
secondary to pressure overload (chronic hypertension, aortic stenosis) and sarcomeric mutations
(HCM) are due to increased cell growth14. The hypertrophy found in families with WPW is also
attributed to increased cell growth. It has been suggested that deposition of a glycogen-like
substance may contribute to cardiac hypertrophy.
Pathogenesis of Familial WPW syndrome
               Families with WPW syndrome exhibit a variable phenotype consisting of cardiac
hypertrophy, preexcitation, and conduction abnormalities. The syndrome is caused by missense
mutations (single nucleotide change) in the gene PKRAG2 which encodes for the gamma-2
subunit of AMPK. There has been an explosion of knowledge on AMPK within the last decade.
Initially it was a surprise that a gene that encodes a metabolic protein was involved in the
generation of cardiac abnormalities. However, given AMPK’s vast array of functions it is
perhaps not so surprising. The cardiac syndrome could be the result of a derangement of one or
more of AMPK’s functions. Pathophysiologically the syndrome due to PKRAG2 resembles other
glycogen   storage   diseases   such   as   Pompe   disease15.  The   triad   of   cardiac   hypertrophy,
preexcitation,   and   conduction   abnormalities   has   been   documented   in   these   diseases16,17.
Therefore, the initial focus on the PRKAG2 induced cardiac syndrome has been on glycogen
storage. Cardiac hypertrophy has been demonstrated by ultrasound in patients with familial
WPW syndrome17. The accumulation of glycogen-like substance has also been seen in the
myocardium   of   these   patients18.  The   increased   thickness   of   the   myocardium   (cardiac
hypertrophy) has been attributed to the excessive deposition of glycogen-like substance as well as
increased myocyte growth, which maybe somewhat different from the hypertrophy seen in HCM
(hypertrophic cardiomyopathy) which is secondary only to increased myocyte growth and
fibrosis. Conduction abnormalities (heart block or slowing of the conduction system) can be
explained by two well established facts. First glycogen is known to be more abundant in the
conduction system compared to the myocardial muscle tissue13. Therefore excess accumulation
of glycogen-like substance could lead to loss of conduction tissue and slowing or block.
Secondly excessive glycogen has been known to be toxic to the conduction system which could
lead to loss of function13.  WPW syndrome in humans is caused by the existence of an accessory
pathway. Initially there is no separation between the atria and the ventricles. During development
either through apoptosis or remodeling the atria separates from the ventricle. It is possible that
the normal developmental process of apoptosis and remodeling doesn’t occur in patients with
familial WPW syndrome. Therefore some myocardial tissue that remains as a connection
between   the   atrium   and   the   ventricle18,19.  AMPK’s   role   in   the   development   of   the
pathophysiology in familial WPW could be a result of gain in function or a loss in function. The
increased amount of glycogen found in the myocardium of these patients suggests a loss of
function if we believe that AMPK activity decreases glycogen stores. Hypertrophy would be
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 3(4): 197-201 (2003)Jasvinder Sidhu and Robert Roberts,                                                                           200
“Genetic Basis and Pathogenesis of Familial WPW Syndrome” 
explainable since a loss of function would lead to an ATP deficient state and increased cell
growth as compensation for increased work load. Conduction abnormalities could arise from the
deposition of glycogen-like substance in the conduction system. Preexcitation maybe a result of a
developmental abnormality as explained above.
Animal model of Familial WPW syndrome
            Transgenic technology has been used in biomedical research over the last 20 years. The
basic idea is to introduce a gene with a known phenotype into an animal in the hope the offspring
will manifest the phenotype. Since the mutation for WPW syndrome was identified interest in
generating a transgenic model for the disease has intensified. Recently a mouse model of this
human disease has been developed (Seidman et al)20.  The generation of a transgenic model
usually is done by cloning the mutated gene of interest along side a powerful promoter in the
expectation that the gene will be overexpressed. In Seidman’s model the gene of interest was the
mutated PRKAG2 gene which encodes for the gamma2 subunit of AMPK and the promoter used
was the alpha-myosin heavy chain promoter. The mice generated recapitulated the human
phenotype with preexcitation and cardiac hypertrophy. Histopathology demonstrated vacuoles
that appear to be like those seen in the human phenotype. Interestingly Seidman et al
demonstrated increased AMPK activity in the mutant transgenic mice versus the wild type
transgenic mice. This would suggest that the missense mutation leads to a gain in function of
AMPK. Electrophysiological studies done on these mice demonstrated the existence of an
accessory pathway consistent with the human form of WPW. Seidman et al proposes that the
glycogen deposition disrupts the annulus fibrosa which is responsible for preexcitation.We
recently developed a transgenic animal (mice) model for human familial WPW syndrome. Our
model has a phenotype of preexcitation and evidence for an accessory pathway. In our model we
were able to induce SVT.
Future Considerations
               Although WPW in its classical form is usually treated with catheter ablation and
conduction abnormalities (AV block or slowing of conduction) can be handled clinically with the
placement of a permanent pacemaker.  There is definitely a role for genetic screening in the
setting of familial WPW syndrome.  Screening will allow the physician to identify individuals
and families at risk for developing AV block and cardiac hypertrophy.  This may become even
more important in the future if novel treatments can be found for this glycogen storage disease.
The development of animal models will also give insight into the molecular mechanisms
involved in the pathogenesis of this disease.  This will also help understand normal development
of the cardiac conduction system.
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